Stoke Therapeutics (STOK) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is STOK's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript…

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulator…

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.65 per share a year ago.…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential wit…

Stoke Therapeutics is positioned for a pivotal 2027 readout of zorevunersen, potentially the first disease-modifying Dravet syndrome therapy. STOK's cash runway extends to early 2028, supported by $420M in cash and a rec…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presen…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presen…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

Corient Private Wealth LP purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ: STOK) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,823 shares of the com…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

Squarepoint Ops LLC acquired a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 29…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Bio…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…

Bank of America Corp DE lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 163.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 543,095 shares…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigat…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

